Moxifloxacin‐Containing Triple Therapy as Second‐Line Treatment for <i>Helicobacter pylori</i> Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate

Abstract

The 7-day moxifloxacin-containing triple therapy produced an unacceptably low eradication rate. Increasing the duration of therapy was expected to increase the eradication rate, but the expected increased did not materialize, most likely because of coincident marked increase in the prevalence of resistance to moxifloxacin. Tailored treatment based on antibiotic susceptibility testing might be more effective in the achievement of high eradication rate when rapid antibiotic resistance such as moxifloxacin is occurring.